PLURISTEM THERAPEUTICS INC (PSTI) Stock Price, Forecast & Analysis
USA - NASDAQ:PSTI - US72940R3003 - Common Stock
PSTI Key Statistics, Chart & Performance
The current stock price of PSTI is 1 USD. In the past month the price decreased by -21.26%. In the past year, price decreased by -69.51%.
PSTI Latest News, Press Relases and Analysis
PSTI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About PSTI
Company Profile
Pluristem Therapeutics, Inc. is a clinical stage company, which engages in cell therapy development. The firm's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The firm's products include PLX-PAD and PLX R18. The firm's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The firm's PLX products are administered using a standard needle and syringe. The firm's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.
Company Info
PLURISTEM THERAPEUTICS INC
Building No. 5, Matam Advanced Technology Park
Haifa 3508409 IL
CEO: Yaky Yanay
Employees: 129
Phone: 972747107171.0
PLURISTEM THERAPEUTICS INC / PSTI FAQ
What does PLURISTEM THERAPEUTICS INC do?
Pluristem Therapeutics, Inc. is a clinical stage company, which engages in cell therapy development. The firm's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The firm's products include PLX-PAD and PLX R18. The firm's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The firm's PLX products are administered using a standard needle and syringe. The firm's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.
Can you provide the latest stock price for PLURISTEM THERAPEUTICS INC?
The current stock price of PSTI is 1 USD. The price decreased by -2.91% in the last trading session.
What is the dividend status of PLURISTEM THERAPEUTICS INC?
PSTI does not pay a dividend.
How is the ChartMill rating for PLURISTEM THERAPEUTICS INC?
PSTI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the analyst forecast for PSTI stock?
8 analysts have analysed PSTI and the average price target is 3.57 USD. This implies a price increase of 257% is expected in the next year compared to the current price of 1.
Can you provide the sector and industry classification for PLURISTEM THERAPEUTICS INC?
PLURISTEM THERAPEUTICS INC (PSTI) operates in the Health Care sector and the Biotechnology industry.
PSTI Technical Analysis
PSTI Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to PSTI. While PSTI belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
PSTI Financial Highlights
Over the last trailing twelve months PSTI reported a non-GAAP Earnings per Share(EPS) of -1.47. The EPS increased by 9.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20373.91% | ||
| ROA | 59.22% | ||
| ROE | 123.02% | ||
| Debt/Equity | 0.6 |
PSTI Forecast & Estimates
8 analysts have analysed PSTI and the average price target is 3.57 USD. This implies a price increase of 257% is expected in the next year compared to the current price of 1.